🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An enduring feature of India’s pharma regulatory regime has been intervention in essential medicine pricing. Yet, when it comes to #Covid vaccines amid the second wave, the scenario is diametrically opposite. Read the full story here: indianexpress.com/article/india/… via The Indian Express

At approximately 90 crore doses per annum, Bharat Biotech says Covaxin set for a boost. However, ramp up to full capacity will take a few months. indianexpress.com/article/india/… via The Indian Express

Reupping this to emphasize that we have new tools that add another layer-even against variants.

#ICYMI

The Govt's latest Covid-19 vaccine bet marks a shift in its aversion to at-risk investment and advance orders. indianexpress.com/article/explai… via The Indian Express

Corbevax Covid-19 Vaccine: How Corbevax is different: our partnership with ⁦Biological E. Limited⁩ ⁦Texas Children's⁩ ⁦BCM_TropMed⁩ indianexpress.com/article/explai…

India is considering whether people can be given a mix of different Covid-19 vaccine doses. What can be the merits of such a programme, and what are the concerns? Prabha Raghavan explains #ExpressExplained indianexpress.com/article/explai…

Centre may renegotiate vaccine prices with SII and Bharat Biotech, Aanchal Magazine and I report. indianexpress.com/article/india/… via The Indian Express

In a series of articles, we have tried to point out the massive disparity in vaccine availability and access to inoculation in India. The disparity is across multiple parameters-- between rich and poor, between states, cities, regions, and between government and private sector

Trials in the UK have found a monoclonal antibody cocktail effective in some patients with severe Covid-19. What is this treatment, how does it compare with plasma therapy, and how much promise does it hold? Prabha Raghavan explains #ExpressExplained indianexpress.com/article/explai…

SEC’s approval of Bharat Biotech's data showing 77.8% efficacy does not mean that Covaxin will now be off restricted-use permission. “Although the company did want a complete authorisation… it was not agreed to." indianexpress.com/article/india/… via The Indian Express

Zydus Cadila applies for emergency use nod for its COVID-19 vaccine indianexpress.com/article/india/… via The Indian Express

Sanofi-GSK's global trials to take place in 13 countries, India to account for 3,000 participants. indianexpress.com/article/india/… via The Indian Express

Spoke to BBC Newshour's James Menendez last evening on WhatsApp banning 2 million accounts in India, the impact of it on #FakeNews and why the platform has gone to court against the Indian govt. Small 2-3 min audio appearance. bbc.in/3xZMTnv (26:33 to 29:50)

Hey guys, a friend was looking for someone who can translate a poem in this piece to Hindi. Let me know if you or anyone you know can help? thewire.in/rights/who-is-…

Need volunteers for a clinical trial. People with 2 doses of Covaxin 3-6 months ago are eligible to enroll in a booster dosing study. Folks in Vellore, Chennai, Bangalore or Delhi willing to consider participating please email [email protected]. Please retweet-thank you

Expectation of more #biotech M&A has stoked hopes of a rebound after the worst H1 for NBI since 2016. The likely M&A targets: firms with drugs already approved or closer to market My story with Amruta Khandekar Medha Singh $PFE $BHVN $GBT $AMGN $CCXI reut.rs/3SKRynM

Though #BharatBiotech is now waiting to launch an all new intranasal vaccine against #Covid_19 pending regulator's nod, its problems with #Covaxin are still far from over ever since #WHO suspended its supply for UN agencies in April (1/n) science.thewire.in/health/exclusi…